

ATEC HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$'000's)

| | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 | Q321 |
|---|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Revenues: | | | | | | | | | | |
| Revenue from products and services | 83,656 | 108,242 | 29,070 | 28,834 | 40,052 | 43,123 | 141,079 | 43,716 | 61,885 | 62,735 |
| Revenue from Int'l supply agreement | 8,038 | 5,185 | 1,045 | 795 | 1,111 | 831 | 3,782 | 405 | 364 | 145 |
| TOTAL REVENUE | 91,694 | 113,427 | 30,115 | 29,629 | 41,163 | 43,954 | 144,861 | 44,121 | 62,249 | 62,880 |
| Cost of revenue | 28,457 | 35,833 | 9,084 | 8,787 | 11,926 | 12,563 | 42,360 | 12,263 | 21,184 | 23,266 |
| Total gross profit | 63,237 | 77,594 | 21,031 | 20,842 | 29,237 | 31,391 | 102,501 | 31,858 | 41,065 | 39,614 |
| Operating expenses (GAAP): | | | | | | | | | | |
| Research & development | 10,988 | 15,486 | 4,169 | 4,237 | 4,984 | 5,355 | 18,745 | 5,801 | 7,839 | 9,391 |
| Sales, general & administrative | 71,505 | 100,077 | 27,583 | 26,468 | 35,380 | 39,725 | 129,156 | 40,426 | 60,659 | 61,494 |
| Litigation-related | 5,683 | 8,549 | 2,643 | 1,304 | 1,560 | 3,045 | 8,552 | 3,335 | 1,167 | 1,209 |
| Amortization of acquired intangible assets | 738 | 698 | 172 | 172 | 172 | 172 | 688 | 172 | 1,208 | 2,012 |
| Transaction-related expenses | 1,550 | - | 4,272 | (181) | 2 | 130 | 4,223 | 1,012 | 4,771 | 373 |
| Restructuring expenses | 1,381 | 60 | - | - | - | - | - | 158 | 1,173 | 256 |
| Gain on Settlement | (6,168) | - | - | - | - | - | - | - | - | - |
| Total operating expenses (GAAP) | 85,677 | 124,870 | 38,839 | 32,000 | 42,098 | 48,427 | 161,364 | 50,904 | 76,817 | 74,735 |
| TOTAL OPERATING LOSS | #### | (47,276) | (17,808) | (11,158) | (12,861) | (17,036) | (58,863) | (19,046) | (35,752) | (35,121) |
| Other income (expense): | | | | | | | | | | |
| Interest and other income (expense), net | (7,139) | (9,865) | (2,874) | (3,032) | (2,768) | (3,700) | (12,374) | (3,827) | (2,410) | (386) |
| Loss on debt extinguishment | (590) | - | - | (1,555) | - | (6,057) | (7,612) | - | - | (7,434) |
| Gain on change in fair value of warrants | - | - | - | - | - | - | - | - | - | - |
| Total other income (expense), net | (7,729) | (9,865) | (2,874) | (4,587) | (2,768) | (9,757) | (19,986) | (3,827) | (2,410) | (7,820) |
| Income (loss) from continuing operations (GAAP) | #### | (57,141) | (20,682) | (15,745) | (15,629) | (26,793) | (78,849) | (22,873) | (38,163) | (42,941) |
| Income tax provision | (1,361) | (239) | 40 | 60 | 40 | 5 | 145 | 30 | 43 | 90 |
| Net loss from continuing operations | #### | (56,902) | (20,722) | (15,805) | (15,669) | (26,798) | (78,994) | (22,903) | (38,206) | (43,031) |
| Income (Loss) from discontinued operations | (167) | (100) | - | - | - | - | - | - | - | - |
| Net loss | #### | (57,002) | (20,722) | (15,805) | (15,669) | (26,798) | (78,994) | (22,903) | (38,206) | (43,031) |
| Recognition of beneficial conversion feature - Series B preferred stock | (13,488) | - | - | - | - | - | - | - | - | - |
| Net loss attributable to common shareholders | #### | (57,002) | (20,722) | (15,805) | (15,669) | (26,798) | (78,994) | (22,903) | (38,206) | (43,031) |
| Net loss per share | (0.82) | (1.09) | (0.33) | (0.25) | (0.24) | (0.35) | (1.18) | (0.26) | (0.39) | (0.43) |
| Basic shares outstanding | 35,315 | 52,234 | 62,568 | 63,713 | 64,761 | 77,098 | 67,020 | 87,223 | 98,541 | 99,571 |

GUIDANCE & COMMENTARY

Full year revenue from products & services, including organic revenue of ~\$208M and EOS-related revenue of ~\$26M, expected to approximate \$234M. International supply agreement ended in August and is expected to contribute ~\$1M for the full year. Total revenue expected to approximate ~\$235M.

Common shares outstanding as of 9/30/21 were 99M. The fully diluted share count as of 9/30/2021 was approximately 132M. Using on the treasury stock method, fully diluted share count was 121M as of 9/30/21. Once converted, the net effect of the convertible debt transaction adds 17M shares (exclude debt of \$316M at that point).

Total revenue expected to grow ~62% for the full year 2021.

EOS PROFORMA GAAP P&L - (\$'000's)

| | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 |
|---|--------------|--------------|--------------|--------------|-----------------|----------------|----------------|
| Revenues: | | | | | | | |
| Revenue from products and services | 4,096 | 6,685 | 7,389 | 9,021 | 27,191 | 6,865 | 7,945 |
| Revenue from Int'l supply agreement | - | - | - | - | - | - | - |
| TOTAL REVENUE | 4,096 | 6,685 | 7,389 | 9,021 | 27,191 | 6,865 | 7,945 |
| Cost of revenue | - | - | - | - | 26,488 | 3,716 | 5,482 |
| Total gross profit | | | | | 703 | 3,149 | 2,463 |
| Operating expenses (GAAP): | | | | | | | |
| Research & development | - | - | - | - | 4,690 | 985 | 2,213 |
| Sales, general & administrative | - | - | - | - | 14,285 | 4,503 | 3,893 |
| Litigation-related | - | - | - | - | - | - | - |
| Amortization of acquired intangible assets | - | - | - | - | 7,124 | 1,796 | 1,979 |
| Transaction-related expenses | - | - | - | - | 10,298 | - | - |
| Restructuring expenses | - | - | - | - | - | - | - |
| Gain on Settlement | - | - | - | - | - | - | - |
| Total operating expenses (GAAP) | | | | | 36,397 | 7,284 | 8,085 |
| TOTAL OPERATING LOSS | | | | | (35,694) | (4,135) | (5,622) |
| Other income (expense): | | | | | | | |
| Interest and other income (expense), net | - | - | - | - | 300 | (116) | (236) |
| Loss on debt extinguishment | - | - | - | - | - | - | - |
| Gain on change in fair value of warrants | - | - | - | - | - | - | - |
| Total other income (expense), net | | | | | 300 | (116) | (236) |
| Loss from continuing operations before taxes | | | | | (35,394) | (4,251) | (5,858) |
| Income tax provision (benefit) | - | - | - | - | 89 | 18 | (18) |
| Net loss | | | | | (35,483) | (4,269) | (5,840) |

* Based on combined information disclosed in SEC filings.

| YOY GROWTH | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 | Q321 |
|-------------------------------------|--------------|--------------|--------------|-------------|--------------|--------------|--------------|--------------|---------------|--------------|
| Revenue from products and services | -3.8% | 29.4% | 26.6% | 10.5% | 42.8% | 38.5% | 30.3% | 50.4% | 114.6% | 56.6% |
| Revenue from Int'l supply agreement | -4.7% | -35.5% | -34.7% | -35.2% | -3.4% | -31.3% | -27.1% | -61.2% | -54.2% | -86.9% |
| Total Revenue | -9.9% | 23.7% | 22.6% | 8.5% | 41.0% | 35.9% | 27.7% | 46.5% | 110.1% | 52.8% |
| Research & development | 82.7% | 40.9% | 12.6% | 17.8% | 16.4% | 37.2% | 21.0% | 39.1% | 85.0% | 88.4% |
| Sales, general & administrative | 3.8% | 40.0% | 32.8% | 8.8% | 33.7% | 39.3% | 29.1% | 46.6% | 129.2% | 73.8% |

Data as of Q3 2021 earnings release on November 4, 2021. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; the Company's ability to meet its financial obligations; and the impact of the COVID-19 pandemic on the Company and economy. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.

atec NON-GAAP RECON - CONSOLIDATED (\$'000's)
INFORMED BY EOS

| | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 | Q321 |
|---|----------------|-----------------|-----------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| ADJUSTED EBITDA | | | | | | | | | | |
| Operating loss, GAAP | (22,440) | (47,276) | (17,808) | (11,158) | (12,861) | (17,036) | (58,863) | (19,046) | (35,752) | (35,121) |
| Depreciation | 6,051 | 6,775 | 2,014 | 2,161 | 2,307 | 2,704 | 9,186 | 3,409 | 5,068 | 5,311 |
| Amortization of intangible assets | 799 | 803 | 440 | 440 | 442 | 440 | 1,762 | 440 | 1,476 | 2,281 |
| Total EBITDA | #### | (39,698) | (15,354) | (8,557) | (10,112) | (13,892) | (47,915) | (15,197) | (29,208) | (27,529) |
| + Stock-based compensation | 5,304 | 10,954 | 3,568 | 4,575 | 4,544 | 4,972 | 17,659 | 4,474 | 11,496 | 10,754 |
| + Purchase accounting adjustments on acquisitions | - | - | - | - | - | - | - | - | 1,763 | 2,577 |
| + Excess & obsolete charges | 3,733 | 8,624 | 1,722 | 1,712 | 1,995 | 1,615 | 7,044 | 2,096 | 2,221 | 2,525 |
| + Contingent consideration fair value adjustment | 846 | 289 | - | - | - | - | - | - | - | - |
| + Litigation-related expenses | 5,683 | 8,549 | 2,643 | 1,304 | 1,560 | 3,045 | 8,552 | 3,335 | 1,167 | 1,209 |
| + Transaction-related expenses | 1,550 | - | 4,272 | (181) | 2 | 130 | 4,223 | 1,012 | 4,771 | 373 |
| + Restructuring expenses | 1,381 | 60 | - | - | - | - | - | 158 | 1,173 | 256 |
| + Gain on settlement | (6,168) | - | - | - | - | - | - | - | - | - |
| Total Adjusted EBITDA | (3,261) | (11,222) | (3,149) | (1,147) | (2,011) | (4,130) | (10,437) | (4,122) | (6,617) | (9,835) |
| <i>Adjusted EBITDA as a % of Revenue</i> | <i>-3.6%</i> | <i>-9.9%</i> | <i>-10.5%</i> | <i>-3.9%</i> | <i>-4.9%</i> | <i>-9.4%</i> | <i>-7.2%</i> | <i>-9.3%</i> | <i>-10.6%</i> | <i>-15.6%</i> |

GUIDANCE & COMMENTARY

| NON-GAAP GROSS PROFIT & GROSS MARGIN | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 | Q321 |
|---|---------------|---------------|---------------|---------------|---------------|---------------|----------------|---------------|---------------|---------------|
| Gross Profit, GAAP | 63,237 | 77,594 | 21,031 | 20,842 | 29,237 | 31,391 | 102,501 | 31,858 | 41,065 | 39,614 |
| + Amortization of intangible assets | 62 | 105 | 268 | 268 | 270 | 268 | 1,074 | 268 | 268 | 270 |
| + Stock-based compensation | 73 | 146 | 107 | 128 | 139 | 138 | 512 | 95 | 235 | 310 |
| + Purchase accounting adjustments on acquisitions | - | - | - | - | - | - | - | - | 1,763 | 2,577 |
| + Excess & obsolescence charges | 3,733 | 8,625 | 1,722 | 1,712 | 1,995 | 1,615 | 7,044 | 2,096 | 2,221 | 2,525 |
| Non-GAAP Gross Profit | 67,105 | 86,470 | 23,128 | 22,950 | 31,641 | 33,412 | 111,131 | 34,317 | 45,552 | 45,296 |
| Gross Margin, GAAP | 69.0% | 68.4% | 69.8% | 70.3% | 71.0% | 71.4% | 70.8% | 72.2% | 66.0% | 63.0% |
| + Amortization of intangible assets | 0.1% | 0.1% | 0.9% | 0.9% | 0.7% | 0.6% | 0.7% | 0.6% | 0.4% | 0.4% |
| + Stock-based compensation | 0.1% | 0.1% | 0.4% | 0.4% | 0.3% | 0.3% | 0.4% | 0.2% | 0.4% | 0.5% |
| + Purchase accounting adjustments on acquisitions | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.8% | 4.1% |
| + Excess & obsolescence charges | 4.1% | 7.6% | 5.7% | 5.8% | 4.8% | 3.7% | 4.9% | 4.8% | 3.6% | 4.0% |
| Non-GAAP Gross Margin | 73.2% | 76.2% | 77.5% | 76.9% | 76.9% | 76.0% | 76.7% | 77.8% | 73.2% | 72.0% |

GM% impacted by consolidation of EOS, which bears lower GMs.

| NON-GAAP OPERATING EXPENSES | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 | Q321 |
|--|---------------|----------------|---------------|---------------|---------------|---------------|----------------|---------------|---------------|---------------|
| Research & Development, GAAP | 10,988 | 15,486 | 4,169 | 4,237 | 4,984 | 5,355 | 18,745 | 5,801 | 7,839 | 9,391 |
| - Stock-based compensation in R&D | 351 | 1,044 | 390 | 548 | 504 | 632 | 2,074 | 498 | 664 | 1,440 |
| - Contingent consideration fair value adjustment | 846 | 289 | - | - | - | - | - | - | - | - |
| Non-GAAP R&D | 9,791 | 14,153 | 3,779 | 3,689 | 4,480 | 4,723 | 16,671 | 5,303 | 7,175 | 7,951 |
| Sales General & Administrative, GAAP | 71,505 | 100,077 | 27,583 | 26,468 | 35,380 | 39,725 | 129,156 | 40,426 | 60,659 | 61,494 |
| - Stock-based compensation in SG&A | 4,880 | 9,764 | 3,071 | 3,899 | 3,901 | 4,202 | 15,073 | 3,881 | 10,597 | 9,004 |
| - Purchase accounting adjustments on acquisitions | - | - | - | - | - | - | - | - | - | - |
| Non-GAAP SG&A | 66,625 | 90,313 | 24,512 | 22,569 | 31,479 | 35,523 | 114,083 | 36,545 | 50,062 | 52,490 |
| Other Operating Expense, GAAP | 3,184 | 9,307 | 7,087 | 1,295 | 1,734 | 3,347 | 13,463 | 4,677 | 8,319 | 3,850 |
| - Litigation-related expenses | 5,683 | 8,549 | 2,643 | 1,304 | 1,560 | 3,045 | 8,552 | 3,335 | 1,167 | 1,209 |
| - Amortization of intangible assets | 738 | 698 | 172 | 172 | 172 | 172 | 688 | 172 | 1,208 | 2,012 |
| - Transaction-related expenses | 1,550 | - | 4,272 | (181) | 2 | 130 | 4,223 | 1,012 | 4,771 | 373 |
| - Restructuring expenses | 1,381 | 60 | - | - | - | - | - | 158 | 1,173 | 256 |
| - Gain on settlement | (6,168) | - | - | - | - | - | - | - | - | - |
| Non-GAAP Other Operating Expense | - | - | - | - | - | - | - | - | (0) | - |
| Total Non-GAAP Operating Expenses | 76,416 | 104,466 | 28,291 | 26,258 | 35,959 | 40,246 | 130,754 | 41,848 | 57,237 | 60,441 |
| Non-GAAP Operating Expenses as a % of Revenue | | | | | | | | | | |
| Research & development | 10.7% | 12.5% | 12.5% | 12.5% | 10.9% | 10.7% | 11.5% | 12.0% | 11.5% | 12.6% |
| Sales, general & administrative | 72.7% | 79.6% | 81.4% | 76.2% | 76.5% | 80.8% | 78.8% | 82.8% | 80.4% | 83.5% |
| Total Non-GAAP Operating Expenses as a % of Revenue | 83.3% | 92.1% | 93.9% | 88.6% | 87.4% | 91.6% | 90.3% | 94.8% | 91.9% | 96.1% |

Q3 opex reflects sustained levels of planned investment through the pandemic - related reduction in surgical volumes and revenue.

| HISTORICAL NON-GAAP U.S. GROSS PROFIT & GROSS MARGIN | 2018 | 2019 | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 |
|--|---------------|---------------|---------------|---------------|---------------|---------------|----------------|---------------|
| U.S. Gross Margin, GAAP | 62,740 | 77,235 | 20,954 | 20,834 | 29,178 | 31,483 | 102,449 | 31,975 |
| + Excess & obsolescence charges | 3,733 | 8,624 | 1,722 | 1,712 | 1,995 | 1,615 | 7,044 | 2,096 |
| Non-GAAP U.S. Gross Margin | 66,473 | 85,859 | 22,676 | 22,546 | 31,173 | 33,098 | 109,493 | 34,071 |
| U.S. Gross Margin, GAAP | 75.0% | 71.4% | 72.1% | 72.3% | 72.9% | 73.0% | 72.6% | 73.1% |
| + Excess & obsolescence charges | 4.5% | 8.0% | 5.9% | 5.9% | 5.0% | 3.7% | 5.0% | 4.8% |
| Non-GAAP U.S. Gross Margin | 79.5% | 79.3% | 78.0% | 78.2% | 77.8% | 76.8% | 77.6% | 77.9% |

EOS NON-GAAP RECON (\$'000's)
imaging

| | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 |
|---|-----------------|----------------|----------------|------|------|------|------|
| ADJUSTED EBITDA | | | | | | | |
| Operating loss, GAAP | (35,694) | (4,135) | (5,622) | | | | |
| Depreciation | 805 | 134 | 200 | | | | |
| Amortization of intangible assets | 7,124 | 1,796 | 1,979 | | | | |
| Total EBITDA | (27,764) | (2,145) | (3,443) | | | | |
| + Stock-based compensation | - | - | - | | | | |
| + Purchase accounting adjustments on acquisitions | 8,600 | - | - | | | | |
| + Excess & obsolete charges | - | - | - | | | | |
| + Contingent consideration fair value adjustment | - | - | - | | | | |
| + Litigation-related expenses | - | - | - | | | | |
| + Transaction-related expenses | 10,298 | - | - | | | | |
| + Restructuring expenses | - | - | - | | | | |
| + Gain on settlement | - | - | - | | | | |
| Total Adjusted EBITDA | (8,866) | (2,145) | (3,443) | | | | |
| <i>Adjusted EBITDA as a % of Revenue</i> | <i>-32.6%</i> | <i>-31.2%</i> | <i>-43.3%</i> | | | | |

| NON-GAAP GROSS PROFIT & GM | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 |
|---|--------------|--------------|--------------|------|------|------|------|
| Gross Profit, GAAP | 703 | 3,149 | 2,463 | | | | |
| + Amortization of intangible assets | - | - | - | | | | |
| + Stock-based compensation | - | - | - | | | | |
| + Purchase accounting adjustments on acquisitions | 8,600 | - | - | | | | |
| + Excess & obsolescence charges | - | - | - | | | | |
| Non-GAAP Gross Profit | 9,303 | 3,149 | 2,463 | | | | |
| Gross Margin, GAAP | 2.6% | 45.9% | 31.0% | | | | |
| + Amortization of intangible assets | 0.0% | 0.0% | 0.0% | | | | |
| + Stock-based compensation | 0.0% | 0.0% | 0.0% | | | | |
| + Purchase accounting adjustments on acquisitions | 31.6% | 0.0% | 0.0% | | | | |
| + Excess & obsolescence charges | 0.0% | 0.0% | 0.0% | | | | |
| Non-GAAP Gross Margin | 34.2% | 45.9% | 31.0% | | | | |

| NON-GAAP OPERATING EXPENSES | Q120 | Q220 | Q320 | Q420 | 2020 | Q121 | Q221 |
|--|---------------|--------------|--------------|------|------|------|------|
| Research & Development, GAAP | 4,690 | 985 | 2,213 | | | | |
| - Stock-based compensation in R&D | - | - | - | | | | |
| - Contingent consideration fair value adjustment | - | - | - | | | | |
| Non-GAAP R&D | 4,690 | 985 | 2,213 | | | | |
| Sales General & Administrative, GAAP | 14,285 | 4,503 | 3,893 | | | | |
| - Stock-based compensation in SG&A | - | - | - | | | | |
| - Purchase accounting adjustments on acquisitions | - | - | - | | | | |
| Non-GAAP SG&A | 14,285 | 4,053 | 3,893 | | | | |
| Other Operating Expense, GAAP | 17,422 | 1,796 | 1,979 | | | | |
| - Litigation-related expenses | - | - | - | | | | |
| - Amortization of intangible assets | 7,124 | 1,796 | 1,979 | | | | |
| - Transaction-related expenses | 10,298 | - | - | | | | |
| - Restructuring expenses | - | - | - | | | | |
| - Gain on settlement | - | - | - | | | | |
| Non-GAAP Other Operating Expense | 0 | 0 | 0 | | | | |
| Total Non-GAAP Operating Expenses | 18,975 | 5,488 | 6,106 | | | | |
| Non-GAAP Operating Expenses as a % of Revenue | | | | | | | |
| Research & development | 17.2% | 14.3% | 27.9% | | | | |
| Sales, general & administrative | 52.5% | 65.6% | 49.0% | | | | |
| Total Non-GAAP Operating Expenses as a % of Revenue | 69.8% | 79.9% | 76.9% | | | | |

* Based on combined information disclosed in SEC filings.



NON-GAAP P&L TREND - CONSOLIDATED (\$'000's)

2018 2019 Q120 Q220 Q320 Q420 2020 Q121 Q221 Q321

| Revenue | 91,694 | 113,427 | 30,115 | 29,629 | 41,163 | 43,954 | 144,861 | 44,121 | 62,249 | 62,880 |
|--|----------------|-----------------|----------------|----------------|----------------|----------------|-----------------|----------------|-----------------|-----------------|
| Non-GAAP cost of sales | 24,589 | 26,957 | 6,987 | 6,679 | 9,522 | 10,542 | 33,730 | 9,804 | 16,697 | 17,585 |
| Non-GAAP gross profit | 67,105 | 86,470 | 23,128 | 22,950 | 31,641 | 33,412 | 111,131 | 34,317 | 45,552 | 45,296 |
| <i>Non-GAAP Gross Margin</i> | <i>73.2%</i> | <i>76.2%</i> | <i>76.8%</i> | <i>77.5%</i> | <i>76.9%</i> | <i>76.0%</i> | <i>76.7%</i> | <i>77.8%</i> | <i>73.2%</i> | <i>72.0%</i> |
| Operating expenses (Non-GAAP): | | | | | | | | | | |
| Research & development, Non-GAAP | 9,791 | 14,153 | 3,779 | 3,689 | 4,480 | 4,723 | 16,671 | 5,303 | 7,175 | 7,951 |
| Sales, general & administrative, Non-GAAP | 66,625 | 90,313 | 24,512 | 22,569 | 31,479 | 35,523 | 114,083 | 36,545 | 50,062 | 52,490 |
| Total operating expenses (Non-GAAP) | 76,416 | 104,466 | 28,291 | 26,258 | 35,959 | 40,246 | 130,754 | 41,848 | 57,237 | 60,441 |
| <i>R&D as % of revenue</i> | <i>10.7%</i> | <i>12.5%</i> | <i>12.5%</i> | <i>12.5%</i> | <i>10.9%</i> | <i>10.7%</i> | <i>11.5%</i> | <i>12.0%</i> | <i>11.5%</i> | <i>12.6%</i> |
| <i>SG&A as % of revenue</i> | <i>72.7%</i> | <i>79.6%</i> | <i>81.4%</i> | <i>76.2%</i> | <i>76.5%</i> | <i>80.6%</i> | <i>78.6%</i> | <i>82.8%</i> | <i>80.4%</i> | <i>83.5%</i> |
| <i>Total OPEX as % of revenue</i> | <i>83.3%</i> | <i>92.1%</i> | <i>93.9%</i> | <i>88.6%</i> | <i>87.4%</i> | <i>91.6%</i> | <i>90.3%</i> | <i>94.8%</i> | <i>91.9%</i> | <i>96.1%</i> |
| Non-GAAP operating loss | (9,311) | (17,996) | (5,163) | (3,308) | (4,318) | (6,834) | (19,623) | (7,531) | (11,685) | (15,146) |
| <i>Op loss as % of revenue</i> | <i>-10.2%</i> | <i>-15.9%</i> | <i>-17.1%</i> | <i>-11.2%</i> | <i>-10.5%</i> | <i>-15.5%</i> | <i>-13.5%</i> | <i>-17.1%</i> | <i>-18.8%</i> | <i>-24.1%</i> |
| Less: Depreciation | 6,051 | 6,775 | 2,014 | 2,161 | 2,307 | 2,704 | 9,186 | 3,409 | 5,068 | 5,311 |
| Adjusted EBITDA | (3,260) | (11,221) | (3,149) | (1,147) | (2,011) | (4,130) | (10,437) | (4,122) | (6,617) | (9,835) |
| <i>Adj EBITDA as % of revenue</i> | <i>-3.6%</i> | <i>-9.9%</i> | <i>-10.5%</i> | <i>-3.9%</i> | <i>-4.9%</i> | <i>-9.4%</i> | <i>-7.2%</i> | <i>-9.3%</i> | <i>-10.6%</i> | <i>-15.6%</i> |



NON-GAAP P&L TREND (\$'000's)

Q120 Q220 Q320 Q420 2020 Q121 Q221

| Revenue | 4,096 | 6,685 | 7,389 | 9,021 | 27,191 | 6,865 | 7,945 |
|--|-------|-------|-------|-------|----------------|----------------|----------------|
| Non-GAAP cost of sales | | | | | 17,888 | 3,716 | 5,482 |
| Non-GAAP gross profit | | | | | 9,303 | 3,149 | 2,463 |
| <i>Non-GAAP Gross Margin</i> | | | | | <i>34.2%</i> | <i>45.9%</i> | <i>31.0%</i> |
| Operating expenses (Non-GAAP): | | | | | | | |
| Research & development, Non-GAAP | | | | | 4,690 | 985 | 2,213 |
| Sales, general & administrative, Non-GAAP | | | | | 14,285 | 4,503 | 3,893 |
| Total operating expenses (Non-GAAP) | | | | | 18,975 | 5,488 | 6,106 |
| <i>R&D as % of revenue</i> | | | | | <i>17.2%</i> | <i>14.3%</i> | <i>27.9%</i> |
| <i>SG&A as % of revenue</i> | | | | | <i>52.5%</i> | <i>65.6%</i> | <i>49.0%</i> |
| <i>Total OPEX as % of revenue</i> | | | | | <i>69.8%</i> | <i>79.9%</i> | <i>76.9%</i> |
| Non-GAAP operating loss | | | | | (9,672) | (2,339) | (3,643) |
| <i>Op loss as % of revenue</i> | | | | | <i>-35.6%</i> | <i>-34.1%</i> | <i>-45.9%</i> |
| Less: Depreciation | | | | | 806 | 194 | 200 |
| Adjusted EBITDA | | | | | (8,866) | (2,145) | (3,443) |
| <i>Adj EBITDA as % of revenue</i> | | | | | <i>-32.6%</i> | <i>-31.2%</i> | <i>-43.3%</i> |

Based on combined information disclosed in SEC filings.

Data as of Q3 2021 earnings release on November 4, 2021. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; the Company's ability to meet its financial obligations; and the impact of the COVID-19 pandemic on the Company and economy. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.